Evolutive and Functional Bases of Menstruation in Women - 2

ConditionMenstruation
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-50
SponsorInstitut National de la Santé Et de la Recherche Médicale, France

About this trial

Menstruation corresponds to the shedding of the uterine lining when fecundation has not occurred. This is a recent evolutionary innovation in primates, and the cellular and genetic changes that led to the acquisition of menstruation are not well understood. Additionally, the uterine lining is poorly characterized in humans across the menstrual cycle, which hinders both evolutionary and medically-relevant analyses.

In this study, the research team are collecting uterine endometrial tissue samples from female donors undergoing uterine surgery for benign conditions, to profile gene expression and gene regulatory elements in the major cell types that compose the uterine lining during the secretive phase of the menstrual cycle. The investigators will compare this data to similar samples collected from other primates at the same time point in the female hormonal cycle.

The objective is to identify genes that have acquired novel regulation and/or expression patterns and which may be involved in menstruation, as well as better characterize the cellular and molecular pathways at work in the uterine lining of women for translational medicine purposes.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Be between 18 and 50 years old.

Have mensturation at the time of their participation

Have given their written consent

Have an indication for surgery of hysteroscopy for removal of a polyp and/or fibroid and/or endometrial, endometrialctomy for presumed benign pathology and/or management of a uterine malformation, scheduled between days 21 and 25 of their menstrual cycle

Disqualifiers

Using an intrauterine device contraceptive method during the study or within the previous three months

To be Pregnant at the time of collection

Have been pregnant in the three months prior to collection

Have had amenorrhoea in the three months prior to collection

Trial design

Design model

Single group

Treatments tested in this trial

  • Hysteroscopy

    Procedure/Surgery

    Samples will be collected from consenting patients undergoing a surgical hysteroscopy for medical purposes

Treatment groups

20 Participants
are divided into 1 treatment group
Group A: Main cohortExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Transcriptomics

Characterisation of genes involved in the evolutionary establishment of menstruation: transcriptome sequencing and identification of genes differentially expressed between menstruating and non-menstruating species in each cell type using DeSEQ analysis (FDR-corrected p-value \< 0.05)

Time frame
18 months
2

Open chromatin analysis

Characterisation of non-coding regulatory elements specifically involved in the evolutionary establishment of menstruation: open chromatin sequencing (ATAC-seq) and identification of non-coding genomic regions differentially activated between menstruating and non-menstruating species in each cell type using DeSEQ analysis (FDR-corrected p-value \< 0.05)

Time frame
18 months

Secondary outcomes

1

Non-coding transcriptomics

Characterisation of non-coding transcripts expressed in the endometrium in menstruating and non-menstruating species in each cell type by transcriptome sequencing, transcript assembly and annotation of expressed non-coding transcripts in each genome

Time frame
18 months
2

3D cell culture - establishment

Obtaining 3D cell cultures ("organoids") to validate the observations of the main objective: proliferation and expansion time-course assessed by bright-field microscopy

Time frame
18 months
3

3D cell culture - structural evaluation

Topographical evaluation of the 3D cell cultures with H/E and PAS staining

Time frame
18 months
4

3D cell culture - cell types evaluation

Profiling of characteristic cell markers in the 3D cell cultures via immunochemistry and immunofluorescence staining (MUC1, Cytokeratin7, EPCAM, Vimentin, CD13, ESR, PGR)

Time frame
18 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.